NEWSStatement Regarding Social Media Posts Concerning Our Group

On December 1st, 2025 we have been reported that videos discussing our Group’s project, “F351,” have been circulating on certain Chinese social media platforms. These posts have led to speculation regarding a potential leak of internal information.

Today, we conducted a thorough review of the video content alongside the leadership of our subsidiaries involved in the project, Gyre Therapeutics and Gyre Pharmaceuticals. Our review confirms that the information discussed in the videos falls entirely within the scope of our Phase Three public disclosure dated May 23, 2025. Furthermore, the content contains no facts that contradict that disclosure.

Conclusion We have concluded that these videos merely represent the independent views of past public records. We believe there has been no leak of undisclosed material facts from our Group.

Note to Investors GNI Group established a “Social Media Policy” on March 18, 2025. All official information is released exclusively through our corporate website and formal disclosure channels. We urge investors to rely solely on our official announcements and to exercise caution regarding unofficial information found on social media.

Inquiries Regarding Project “F351” Please be advised that Gyre Therapeutics is a U.S.-listed subsidiary. To ensure proper governance and compliance with parent-subsidiary listing rules, Gyre Therapeutics will take precedence in releasing timely disclosures regarding the progress of Project “F351.”

As it is inappropriate for the parent company to disclose information before the listed subsidiary does, please direct all inquiries regarding this matter to Gyre Therapeutics via the form below.

[Contact Information (Gyre Therapeutics)]
Please submit inquiries via the following
URL: https://www.gyretx.com/contact/